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H
DObjective: Increased blood lactate levels reflect tissue oxygen debt and might be indicative of low cardiac
output. We hypothesized that the rate of increase in serum lactate would be an ideal marker to discriminate
between infants at high and low risk of a poor outcome after surgical repair of congenital heart disease using
cardiopulmonary bypass.
Methods: In the present prospective, observational study in a pediatric cardiac intensive care unit, infants
(aged<12months) undergoing cardiac surgery had serial whole blood lactate levels measured with every arterial
blood gas drawn for the first 24 postoperative hours. The composite poor outcome included death, the need for
extracorporeal support, and dialysis.
Results: The lactate levels were measured in 231 infants; 19 infants (8.2%) had a poor outcome. A lactate
increase rate of 0.6 mmol/L/h had very good discriminatory ability (area under the curve [AUC], 0.89) with
a sensitivity of 90%, specificity of 84%, positive predictive value (PPV) of 34%, and negative predictive value
(NPV) of 99%. Similar results were obtained for subgroups stratified by 1- or 2-ventricle heart disease and risk
adjustment for congenital heart surgery (RACHS-1) score. In neonates (age<30 days) with single-ventricle
physiology (n ¼ 43, poor outcome ¼ 8), a lactate increase of 0.6 mmol/L/h had near perfect discriminatory
ability (AUC 0.99) with a sensitivity of 100%, specificity of 51%, PPV of 32%, and NPV of 100%.
In 2-ventricle neonates (n ¼ 43, poor outcome ¼ 5), a lactate increase of 0.6 mmol/L/h also had near perfect
discriminatory ability (AUC, 0.99), with a sensitivity of 100%, specificity of 90%, PPV of 56%, and NPV
of 100%.
Conclusions: The postoperative lactate increase rate allows discrimination between infants at high and low risk
of morbidity and mortality after congenital heart disease surgery, and the lactate level can be followed serially
for the treatment response. (J Thorac Cardiovasc Surg 2014;148:589-95)Clinical indicators reflecting tissue perfusion and systemic
oxygen delivery are needed after surgery for congenital
heart disease (CHD). The ideal indicator would have a
high predictive value for outcome, would allow for early
detection of tissue ischemia before injury, and could be
monitored serially to assess the response to therapeutic
interventions. Blood lactate has been studied as a potential
clinical marker, particularly in children after cardiac
surgery. Lactate is formed from pyruvate as the final
product of glycolysis. Under aerobic conditions, lactate is
converted back to pyruvate by mitochondrial oxidation.
Under anaerobic conditions, cellular lactate levels increase,
leading to increased serum lactate levels.1 Thus, hyperlacte-
mia might reflect tissue oxygen debt.e University of Michigan Congenital Heart Center, C. S. Mott Children’s
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The Journal of Thoracic and CaMultiple studies in the pediatric data have examined
the utility of blood lactate levels as both positive and
negative predictors of outcome after surgery for CHD.2-10
However, most of these studies had important limitations,
including low patient numbers, that compromised their
ability to adequately assess the predictive value of an
elevated lactate level. Furthermore, several studies
combined data from children of all ages in their analyses.
This could have been problematic because the
susceptibility to tissue oxygen debt and normal lactate
levels vary with age.11,12 Finally, the point at which the
lactate level is measured during the clinical course and
the chronicity of the lactate measurements differed from
study-to-study, making comparisons among smaller studies
difficult.
More than 1 decade ago, we published a prospective
study on the predictive value of serial lactate levels in a
small cohort of 46 neonates after complex congenital heart
surgery at the University of Michigan.13 In that limited
sample, the rate of increase in serum lactate was identified
as an early marker of increasing tissue oxygen debt that
was predictive of poor outcome. Despite the potential
benefits of an increase in lactate as a predictor of poor
outcome, these results have not been reproduced on a largerrdiovascular Surgery c Volume 148, Number 2 589
Abbreviations and Acronyms
AUC ¼ area under the curve
CBP ¼ cardiopulmonary bypass
CHD ¼ congenital heart disease
CICU ¼ cardiac intensive care unit
ECMO ¼ extracorporeal membrane oxygenation
ICU ¼ intensive care unit
IQR ¼ interquartile range
NPV ¼ negative predictive value
PPV ¼ positive predictive value
RACHS-1 ¼ risk adjustment for congenital heart
surgery
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Dscale or in a broader patient population. In the present
study, we sought to re-evaluate the utility of both initial
and serial lactate measurements in a larger cohort of infants
after cardiopulmonary bypass (CPB) for congenital heart
surgery. We hypothesized that rate of increase in serum
lactate would have a strong predictive value for the outcome
and would proceed maximal tissue oxygen debt.METHODS
Patients
We conducted a prospective, observational study of infants (<12
months of age) after surgical repair of CHD requiring CPB. A total of
231 nonconsecutive infants were enrolled in the study from June 2010
to September 2011. Nonconsecutive enrollment resulted because of
parental refusal (3 infants) or parental unavailability for consent (18
infants). Parental consent was obtained before data collection, and the
institutional review board of the University of Michigan approved the
research protocol. All infants were required to be 37 weeks’ corrected
gestational age and to weigh>2 kg before enrollment. Infants requiring
extracorporeal membrane oxygenation (ECMO) in the operating room
before arrival in the cardiac intensive care unit (CICU) were excluded
from the study. Only those patients in whom ECMO was initiated
emergently after postoperative CICU admission were included in the
present analysis.
Lactate Measurements
Serial, arterial, whole blood lactate levels were collected per CICU
protocol at the discretion of the treating clinician. At our center, lactate
levels were obtained routinely with each arterial blood gas drawn. All
lactate levels measured in the initial, postoperative 24 hours were included
in the present study. Whole blood lactate was measured using a pediatric
blood gas analyzer (ABL 800 Flex; Radiometer, Brønshøj, Denmark) for
each sample. For serum lactate levels within a range of 0 to 30 mmol/dL,
this pediatric blood gas analyzer is accurate, with an r2 of 0.95, and precise,
with a coefficient of variance of 0% to 2% compared with laboratory-
measured lactate values. A priori analyses were planned to assess the
predictive values of both the initial postoperative lactate level and the
maximal rate of increase in the lactate level. The initial lactate level was
drawn within 1 hour of arrival in the CICU postoperatively. The lactate
increase rate was calculated as the difference between the consecutive
lactate measurements divided by the interval between the measurements.
The maximal rate of lactate increase was expressed as the largest increase
between 2 consecutive measurements divided by interval during the first 24
postoperative hours.590 The Journal of Thoracic and Cardiovascular SurgOutcome Variable
The primary outcome variable (‘‘poor outcome’’) was a composite of
death during hospitalization, the need for ECMO support initiated after
admission to the CICU, and the initiation of renal dialysis. In our CICU,
few infants have significant preoperative kidney disease, and most cases
of renal injury requiring dialysis result from acute kidney injury caused
by tissue ischemia, which has been reported in other studies.14 Although
not inclusive of all significant postoperative events that could result from
postoperative ischemia, this composite outcome was specifically selected
because the individual outcomes can be easily assessed as positive or
negative, and the endpoints are clinically relevant. A subject was classified
as having a poor outcome based on the appearance of any 1 component of
the composite outcome. Secondary outcomes included the need for an
unplanned cardiac reoperation, duration of tracheal intubation, and length
of intensive care unit (ICU) and total hospital stays.
Statistical Analysis
Descriptive statistics are reported as frequencies with percentages for
categorical variables and medians with interquartile ranges (IQRs) for
continuous variables. The demographic and patient surgical characteristics
between the 2 outcome groups (poor and good outcome) were compared
using the chi-square test or Fisher’s exact test, as appropriate, for the
categorical variables and the Wilcoxon rank sum test for continuous
variables. Using receiver operating characteristic curves, the optimal levels
for the initial postoperative lactate level and maximal hourly increase in
lactate were determined as the best combination of sensitivity and
specificity for significant discrimination between patient outcomes. To
ascertain the predictive ability of the optimal levels, the area under the
curve (AUC), sensitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV) for each optimal value were calculated,
and the relative risks with the 95% confidence intervals (CIs) for a poor
outcome are also reported. Similarly, additional subgroup analyses planned
a priori included evaluating the predictive value of the initial lactate level
and increase in lactate stratified by single- and 2-ventricle subjects, single-
and 2-ventricle neonates (age<30 days), and risk adjustment for congenital
heart surgery (RACHS-1) score.15 Finally, after stratifying the cohort by
the high- and low-risk lactate measurements, other clinical outcomes
were compared using the chi-square test or Fisher’s exact test, as
appropriate, for the categorical variables and the Wilcoxon rank sum test
for continuous variables. All analyses were performed using Statistical
Analysis Systems, version 9.3 (SAS Institute, Cary, NC), with statistical
significance set at P<.05 using 2-sided tests.RESULTS
A total of 231 subjects were analyzed in the present study.
Of these 231 subjects, 212 had good outcomes and 19
(8.2%) met 1 of the criteria for a composite poor
outcome, including 9 (3.9%) who required post-CICU
admission ECMO support, 7 who required renal dialysis
(3.0%), and 11 (4.8%) who died (Figure 1). The interval
between surgery and the occurrence of the composite
poor outcome was a median of 1 day (IQR, 0-63).
Specifically, the interval from surgery to a poor outcome
was a median of 1 day (range, 0-2) for patients needing
ECMO support, a median of 3 days (range, 2-15) for
patients requiring renal dialysis, and a median of 24 days
(range, 1-197) for the patients who died. Six additional
subjects whose parents had agreed to the study were
excluded from the analysis after requiring ECMO support
in the operating room before the CICU admission.ery c August 2014
FIGURE 1. Venn diagram illustrating the distribution of poor outcomes
among the 19 subjects meeting the composite poor outcome endpoint.
ECMO, Extracorporeal membrane oxygenation.
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DThe demographics and patient surgical data are listed in
Table 1. Significant differences between the outcome
groups included younger age, higher RACHS-1 scores,TABLE 1. Demographic and clinical characteristics (n ¼ 231)
Characteristics All
Outcome
P
value*
Poor
(n ¼ 19)
Good
(n ¼ 212)
Male gender 107 (46.3) 11 (57.9) 96 (45.3) .29
White race 161 (69.7) 12 (63.2) 149 (70.3) .75
Age at surgery (d) 82 (8-148) 9 (5-34) 92 (9.5-148.5) .02
RACHS-1 score .01y
1 or 2 89 (38.5) 2 (10.5) 87 (41.0)
3 59 (25.5) 2 (10.5) 57 (26.9)
4 29 (12.6) 5 (26.3) 24 (11.3)
5 or 6 39 (16.9) 7 (36.8) 32 (15.1)
NA 15 (6.5) 3 (15.8) 12 (5.7)
Single- vs 2-ventricle
disease
.02
Single 69 (29.9) 10 (52.6) 59 (27.8)
Two 162 (70.1) 9 (47.4) 153 (72.2)
Intraoperative
CPB (min) 93 (68-129) 111 (75-162) 92.5 (66.5-126) .22
Aortic crossclamp
time (min)
39 (25-61) 38 (33-56) 39.5 (24.5-61) .87
Hypothermic
cardiac arrest
59 (25.5) 11 (57.9) 48 (22.6) .002
Data are presented as n (%) for categorical variables and median (interquartile range)
for continuous variables. RACHS-1, Risk adjustment for congenital heart surgery;
CPB, cardiopulmonary bypass. *P value from chi-square test or Fisher’s exact test
for categorical variables and Wilcoxon rank sum test for continuous variables for
comparison of each characteristic between 2 outcome groups. yComparison for
RACHS-1 classification was made as 1 to 4 versus 5 or 6, with P value from Fisher’s
exact test.
The Journal of Thoracic and Camore single-ventricle heart disease, and a greater percent-
age of patients undergoing circulatory arrest in the poor
outcome group. A post hoc chart review found that no
patient was given ECMO because of a lactate level alone.
The lactate levels were available to the treating clinician;
however, factors other than lactate were reported as the
primary indication for the initiation of ECMO support
in each case. The indications for ECMO were cardio-
pulmonary resuscitation without regaining a perfusing heart
rhythm or adequate blood pressure (extracorporeal cardio-
pulmonary resuscitation) in 4 patients, successful cardio-
pulmonary resuscitation with subsequent hemodynamic
status judged to be unstable in 2 patients, and inadequate
hemodynamic status despite maximal, nonmechanical
support in 3 patients. The indications for renal dialysis
were severe edema with oliguria in 5 subjects and oliguria
with electrolyte abnormalities in 2 subjects.
The median number of lactate assessments in the first
postoperative 24 hours was 10 per patient (minimum 6,
maximum 25). The median initial lactate value among the
poor outcome patients was 6.2 mmol/L (IQR, 2.2-7.5).
The initial lactate level in the good outcome group was
significantly lower at 2.0 mmol/L (IQR, 1.4-4; P<.0001).
During the first 24 postoperative hours, the median peak
lactate value among the poor outcome patients was 10.9
mmol/L (IQR, 6.5-17) compared with a median peak lactate
value of 2.4 mmol/L (IQR, 1.7-4.3) among the good
outcome subjects (P< .0001). The maximal increase in
serum lactate was calculated for each patient. Among those
with a poor outcome, the median peak lactate increase was
2 mmol/L/h (IQR, 0.7-3.4) compared with 0.25 mmol/L/h
(IQR, 0.1-0.5) among those with a good outcome
(P < .0001). The median interval between consecutive
measurements used to calculate the maximal increase in
lactate was 1.2 hours (IQR, 0.8-1.5) in the poor outcome
group and 2.1 hours (IQR, 1.4-3.2) in the good outcome
group (P<.001).
The optimal levels that discriminated between patient
outcomes for both the initial postoperative lactate level
and the maximal hourly lactate increase were determined
using receiver operating characteristic curves (Figure 2).
An optimal initial lactate level of 5 mmol/L showed good
discrimination between the outcome groups, with an AUC
of 0.78 (95% CI, 0.66-0.91), a sensitivity of 68.4%, and
a specificity of 85.8% for a poor outcome. An optimal pre-
dictive increase in lactate of 0.6 mmol/L/h demonstrated
very good discriminatory ability, with an AUC of 0.89
(95% CI, 0.78-1.00), a sensitivity of 89.5%, and a
specificity of 84.4% for a poor outcome. For both cutoff
values, the PPV was relatively low, but the NPV was very
high. Also, both the initial lactate level and the rate of
increase conferred an increase in the relative risk of a
poor outcome, with a greater increase in the risk of
increasing lactate levels (Table 2).rdiovascular Surgery c Volume 148, Number 2 591
FIGURE 2. Receiver operator characteristic curves for (A) initial lactate value and (B) maximal hourly increase in lactate. AUC, Area under the curve.
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DA total of 50 patients had lactate levels that increased
faster than 0.6 mmol/L/h. In 45 of 50 patients, the lactate
increase was measured a median of 4.6 hours (IQR,
2.1-9.4) before reaching their peak lactate level after the
initial increase. In the remaining 5 patients, the peak lactate
level also constituted the end of the maximal calculated
increase. Thus, in 90% of patients with an increasing lactate
level, the increase preceded the maximal tissue oxygen
debt, as measured by the peak lactate level that followed
the lactate increase.
We examined the interaction between the initial and
increasing lactate levels. For patients who had a lactate
increase of 0.6 mmol/L/h, the initial lactate value was a
median of 4.9 mmol/L (IQR, 2.6-7.0). For patients who
did not have a lactate increase of 0.6 mmol/L/h, the
median initial lactate level was 1.8 mmol/L (IQR,
1.4-3.3). The correlation between high initial lactate values
and increasing lactate values among all subjects was
analyzed. Of the 50 patients with a lactate increase of
0.6 mmol/L/h, 25 patients did not have an initial lactate
of 5 mmol/L. Thus, although the correlation between
the 2 groups was significant (P<.001), a significant propor-
tion of patients had an increasing lactate level who had not
presented with an initial high lactate level. That suggests
that although some subjects have a significant tissue oxygen
debt because of their intraoperative course that extends
postoperatively, another, equally large, patient group will
has a tissue oxygen debt that primarily evolves in the
postoperative period. Among the 19 subjects with a poor
outcome, 12 (63.2%) had both high initial and increasing
lactate levels, 5 (26.3%) had increasing lactate levels but
had low initial lactate levels, 1 (5.2%) had a high lactateTABLE 2. Most predictive blood lactate measurements for a poor outcom
Lactate Cutoff value* (mmol/L)
Initial lactate level 5
Maximal change in lactate level/h 0.60
PPV, Positive predictive value; NPV, negative predictive value; RR, relative risk; CI, con
operating characteristic curves.
592 The Journal of Thoracic and Cardiovascular Surglevel that did not increase and 1 (5.2%) had neither a
high initial nor increasing lactate level. The predictive value
of a combined high initial and increasing lactate was
assessed. The combined lactate measure had an AUC of
0.79, 63.2% sensitivity, 93.9% specificity, 48.0% PPV,
and 96.6%NPV. Thus, the combined measure had a greater
PPV than either lactate measure alone but had a discrimina-
tory ability similar to the initial lactate level and inferior to
an increasing lactate level.
As an additional analysis, we limited the primary
outcome to include only emergent ECMO support and
death. An initial lactate level of 5 mmol/L demonstrated
good discrimination between outcomes with an AUC of
0.78 (95% CI, 0.65-0.91), a sensitivity of 66.7%, and a
specificity of 85.4%. An increase in the lactate level of
0.6 mmol/L demonstrated very good discrimination, with
an AUC of 0.88 (95% CI, 0.76-1.00), a sensitivity of
88.9%, and a specificity of 84.0%. These results are
significant and similar to, but slightly less precise than,
those using a composite outcome, including dialysis.
Subgroup Analyses
The diagnostic performance of the initial lactate and
increase in lactate was assessed after stratifying the subjects
by single- versus 2-ventricle heart anatomy and physiology.
Similar to the overall cohort, an increase in lactate of
0.6 mmol/L/h again demonstrated superior discriminatory
ability and had a high NPV but low PPV. In subjects with
the single-ventricle physiology, an initial lactate cutoff
value of 5 mmol/L had an AUC of 0.74, PPV 30%,
and NPV 95%. In single-ventricle subjects, a increase
in the lactate cutoff of 0.6 mmol/L/h had an AUC 0.87,e (n ¼ 231, poor outcome, n ¼ 19)
PPV (%) NPV (%) RR (95% CI)
30.2 96.8 9.5 (3.8-23.5)
34.0 98.9 30.8 (7.4-128.7)
fidence interval. *The optimal cutoff value was obtained from generating receiver
ery c August 2014
TABLE 3. Most predictive blood lactate concentration for poor outcome stratified by single- or 2-ventricle repair in neonates (n ¼ 86)
Lactate level Cutoff value (mmol/L) AUC Sensitivity (%) Specificity (%) PPV (%) NPV (%)
All neonates
Initial lactate level 5 0.69 76.9 61.6 26.3 93.7
Maximal change in lactate level/h 0.60 0.98 100 71.2 38.2 100
Single-ventricle disease (n ¼ 43)
Initial lactate level 5 0.83 100 48.6 30.8 100
Maximal change in lactate level/h 0.60 0.99 100 51.4 32 100
Two-ventricle disease (n ¼ 43)
Initial lactate level 5 0.44 40 73.7 16.7 90.3
Maximal change in lactate level/h 0.60 0.99 100 89.5 55.6 100
AUC, Area under the curve; PPV, positive predictive value; NPV, negative predictive value.
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DPPV 32%, and NPV 98%. In subjects with 2-ventricle
physiology, an initial lactate cutoff value of 5 mmol/L had
an AUC of 0.80, PPV 31%, and NPV 97%. In 2-ventricle
subjects, a lactate increase cutoff value of 0.6 mmol/L/h
had an AUC 0.91, PPV 36%, and NPV 99%.
The predictive performance of the lactate values in the
subgroup of neonatal patients (age<30 days) both overall
and stratified by single- versus 2-ventricle physiology is
summarized in Table 3. For all neonates, an increase in
lactate of 0.6 mmol/L/h had near-perfect discrimination
between outcomes (AUC, 0.99). There was again a
relatively low PPVand high NPV for both the initial lactate
and increase in lactate level. The notable exception was
a PPV of 56% for an increasing lactate level in the
2-ventricle, neonatal cohort.
Similar to the other analyses, in groups stratified by
RACHS-1 score, the AUCs indicated good discriminatory
ability for the increase in lactate for both low and high
RACHS-1 subgroups and high NPVand limited PPV. In sub-
jects with a RACHS-1 score 1 to 4, an initial lactate cutoff
value of 5 mmol/L had an AUC of 0.82, PPV 43%, and
NPV 98%. Those with a RACHS-1 score of 5 to 6 had an
AUC of 0.91, PPV of 31%, and NPV of 99%. In subjects
with a RACHS-1 score of 1 to 4, a lactate increase of 0.6
mmol/L/h had an AUC of 0.78, PPV of 24%, and NPV of
99%. Those with a RACHS-1 score of 5 to 6 had an AUC
of 0.85, PPVof 32%, andNPVof 95%. Additionally, we per-
formed a separate analysis stratifying by the operative use of
circulatory arrest. The results of that analysis were nearly
identical to the analysis stratified by the RACHS-1 score,
likely reflecting the large majority of the infants requiring
circulatory arrest who had a RACHS-1 score of 5 or 6.
Secondary Outcomes
A total of 33 patients required an unplanned cardiac
reoperation, with 16 of these occurring in patients who
had demonstrated an increase in lactate>0.6 mmol/L/h.
An increasing lactate level increased the odds of an
unplanned reoperation by 4.5 (95% CI, 2.1-9.9; P<.0001).
When stratified by lactate values, the median duration of
mechanical ventilation, total ICU stay, and total hospitalThe Journal of Thoracic and Castay were significantly longer in both the high initial lactate
and the increasing lactate groups compared with the low
lactate groups. For subjects with an initial lactate level of
5 mmol/L compared with<5 mmol/L, the mechanical
ventilator duration was a median of 5 days (IQR, 4-11)
versus 3 days (IQR, 2-6; P< .0001), the total ICU stay
was a median of 11 days (IQR, 6-18) versus 6 days (IQR,
3-10; P<.0001), and the total hospital stay was a median
of 21 days (IQR, 16-38) versus 11 days (IQR, 7-18.5;
P < .0001). For subjects with a lactate increase of
0.6 mmol/L/h compared with <0.6 mmol/L/h, the
mechanical ventilator duration was a median of 6.5 days
(IQR, 5-11) versus 3 days (IQR, 2-5; P<.0001), the total
ICU stay was a median of 12.5 days (IQR, 7-18) versus
5 days (IQR, 3-10; P < .0001), and the total hospital
stay was a median of 22.5 (IQR, 16-36) versus 11 days
(IQR, 7-17; P<.0001).
DISCUSSION
The present study is the largest report of serial lactate
levels in infants after heart surgery with CPB. Our results
have indicated that increasing lactate levels are very good
discriminators for the outcome in infants after heart surgery.
In the overall cohort and all subgroups analyzed, the
absence of increasing lactate levels had a very high
association with a good outcome (strong NPV). In the
absence of rapidly increasing lactate levels, clinicians can
be confident that their current treatment approach is likely
adequate in preventing tissue ischemia and will be
associated with good outcomes. In contrast, the presence
of rapidly increasing lactate levels was only a modest
predictor of a poor outcome in all groups. This low PPV
was not particularly surprising, because a PPV is contingent
on the prevalence of the outcome in the population, and
poor outcomes have a relatively low prevalence after
pediatric cardiac surgery. In addition, in our institution,
we often attempt to intervene in patients with increasing
lactate levels by introducing therapies aimed at improving
systemic oxygen delivery. This clinical approach might
have confounded the relationship between the increasing
lactate levels and the composite poor outcome. However,rdiovascular Surgery c Volume 148, Number 2 593
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of increasing lactate levels still was found to have excellent
discriminatory ability in differentiating between low-risk
patients and high-risk patients in whom the clinical
outcome might still be in the balance and difficult to
predict. In this high-risk group, therapeutic interventions
should be considered when increasing lactate levels are
detected.
Neonates with 2-ventricle physiology were a notable
exception to the relatively low PPV of increasing lactate
levels, with a 56% PPV for a poor outcome. This significant
finding should guide the clinician to re-evaluate potential
therapeutic interventions to prevent poor outcomes in
neonates with 2-ventricle heart disease in whom lactate is
increasing.
Several previous studies have considered the predictive
ability of postoperative lactate levels using varying lactate
measurements, including the initial lactate level,2-6,8,9
peak lactate level,2,3,6,13 and ‘‘lactime,’’ a measurement of
serum lactate clearance over time as evidenced by the
total duration of lactate higher than a certain cutoff level,
often 2 mmol/L.2,3 These studies examined lactate levels
over varying postoperative periods from 24 to 72 hours.
The initial lactate level might be indicative of the
patient’s immediate postoperative condition; however, the
initial lactate level has often been found to have only
modest predictive value, likely reflecting the physiologic
changes that can occur in the immediate postoperative
period. Our data have also demonstrated that the initial
lactate level appears to be a reasonable predictor but was
inferior to an increase in lactate in discriminating between
groups. Peak lactate measurements have demonstrated
greater predictive values than the initial lactate levels for
a poor outcome. However, the peak lactate level is a
suboptimal clinical marker, given that the maximal tissue
oxygen debt has likely already occurred by the time of
measurement and intervention might not prevent the
resulting sequelae of tissue ischemia. Similarly, multiple
studies have examined lactime. Although lactime has
been shown to have good predictive value, similar to that
of the peak lactate level, the optimal opportunity to
prevent damage from tissue ischemia might have passed
by the time the measurement has been obtained.
In 90% of our patients with a significant increase in
serum lactate, the measured increase preceded the eventual
resulting peak after the increase in serum lactate, with a
median lead time of 4.6 hours. This interval could allow
additional therapies to be initiated, targeting improved
tissue oxygen delivery, before maximal tissue ischemia
and its sequelae have occurred. Thus, lactate measurements
that are indicative of peak tissue ischemia, such as peak
lactate and lactime, might have good ability to predict
the outcome, but they are less likely to allow effective
intervention. An increasing lactate level might allow594 The Journal of Thoracic and Cardiovascular Surgprevention of patient morbidity by allowing an early
therapeutic response, making this a more desirable clinical
marker.
Our result demonstrating an increased odds of unplanned
cardiac reoperation with an increasing lactate level is
also of interest. Unplanned reinterventions were recently
demonstrated to have a strong association with increased
mortality in neonates with CHD.16 Increasing lactate levels
could prompt earlier evaluation and consideration for
reoperation. This approach might decrease the period that
an infant is exposed to inadequate tissue oxygenation and
potentially preserve end-organ function after heart surgery.
Individual center practice patterns will vary in their
response to lactate levels. Thus, each individual ICU that
monitors serial lactate levels must determine which
measured increase in lactate will best predict the outcome
in their own center. Benchmarking the lactate levels and
using them to improve outcomes has been demonstrated
to be effective in improving the outcomes in other
centers.17,18
Study Limitations
The present study had several limitations. First, as
previously stated, lactate levels were routinely measured
with every arterial blood gas draw in our CICU. Therefore,
infants who appeared more critically ill likely had their
lactate level measured more often than healthy-appearing
postoperative infants, leading to a potential selection bias.
Second, treating clinicians were not blinded to the lactate
levels and might have factored the lactate measurements
into their treatment decision-making. Third, this was a
single-institution study performed at a large referral center,
and these results might not be generalizable to other
pediatric heart centers. Although we recognize these
limitations, we believe that the large sample size of our
studyminimized some of these limitations and that a change
in serial lactate levels remains a strong discriminator for
the clinical outcome. Furthermore, because the treating
clinicians had access to these measurements, our results
actually demonstrated the ‘‘real world’’ predictive ability
of lactate levels in CICU infants, and the results are no
less compelling.
CONCLUSIONS
In infants after surgical repair of CHD using CPB, an
increase in lactate allows excellent discrimination between
high- and low-risk groups for a poor outcome, has a high
NPV, precedes post-peak tissue oxygen debt, potentially
allowing for early therapeutic intervention, and allows
serial monitoring to assess the treatment response. These
factors make an increasing lactate level a clinically viable
marker for the outcome and a potential trigger for
therapeutic modification. Similarly, the absence of an
increasing lactate level would be a reassuring finding.ery c August 2014
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DInfants with increasing lactate levels constitute a group
at significant risk of morbidity and should prompt
consideration of additional treatment options. Future
multivariate studies to assess the interaction of lactate
levels with other clinical markers are warranted to further
improve our ability to predict the clinical outcomes in this
patient population.
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